<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312299</url>
  </required_header>
  <id_info>
    <org_study_id>2PR1210608</org_study_id>
    <nct_id>NCT00312299</nct_id>
  </id_info>
  <brief_title>Posterior Capsule Opacification Study</brief_title>
  <official_title>Posterior Capsule Opacification After Implantation of Square Edge PMMA, Round Edge PMMA and Acrysof Intraocular Lenses: Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurolab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurolab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First object is to compare square edge PMMA with round edge PMMA IOL where the materials are
      same. Next objective is to compare square edge PMMA IOL with Acrysof IOL where the materials
      are different
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cataract is the vision impairing disease characterized by gradual, progressive thickening of
      the lens. Posterior Capsular Opacification (PCO) remains the most frequent long term
      complication. This is initiated by the migration and proliferation of residual lens
      epithelial cells from the lens equator in the space between the posterior capsule and
      intraocular lens (IOL)

      The combination of IOL material and a sharp edged design is effective in preventing PCO.
      Aurolab has developed 360 degree square edge IOL with polymethyl methacrylate (PMMA)

      100 bilateral senile cataract patients are going to be recruited. First group of 50 patients
      will receive square edge PMMA in one eye and round edge PMMA in fellow eye. Another group of
      50 patients will receive square edge PMMA in one eye and acrysof in fellow eye. PCO will be
      assessed during each follow up using EPCO software.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCO</measure>
    <time_frame>1 Day, 1 Month, 6 Month, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>1 Day, 1 Month, 6 Month, 1 Year, 2 Year, 3 Year, 4 Year, 5 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Arm 1 A - Square edge PMMA IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patientes will recieve square edge PMMA IOL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In group 1, 50 eyes will receive round edge PMMA IOL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In group 2, 50 eyes will receive square edge PMMA IOL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In group 2, 50 eyes will receive acrysof IOL</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Square edge PMMA IOL</intervention_name>
    <description>Arm 1 A - Square edge PMMA IOL</description>
    <arm_group_label>Arm 1 A - Square edge PMMA IOL</arm_group_label>
    <other_name>TrueEdge IOL</other_name>
    <other_name>S3602SQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Round edge PMMA IOL</intervention_name>
    <description>Round edge PMMA IOL</description>
    <arm_group_label>1B</arm_group_label>
    <other_name>S3602</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acrysof IOL</intervention_name>
    <description>Acrysof IOL</description>
    <arm_group_label>2B</arm_group_label>
    <other_name>SA60AT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>square Edge PMMA IOL</intervention_name>
    <description>Square edge PMMA intra ocular lens</description>
    <arm_group_label>Arm 1 A - Square edge PMMA IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Square Edge PMMA IOL</intervention_name>
    <description>Square Edge PMMA IOL lens</description>
    <arm_group_label>2A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 to 65 years

          -  Bilateral senile cataract

          -  Pupil should be at least 7mm dilated

          -  Nuclear sclerosis grade I, II and III

          -  Patient willing for second eye surgery within 3 months

        Exclusion Criteria:

          -  Debilitated old patients

          -  Cardiac and serious illness

          -  Intraoperative complications including PC rent, Zonular dialysis and Rhexis tear

          -  Inherent zonular weakness

          -  Glaucoma patients

          -  Relative afferent papillary defect (RAPD)

          -  Shallow anterior chamber

          -  Pseudoexfoliation

          -  Traumatic cataract

          -  Uveitis and complicated cataract

          -  One eyed patients

          -  Corneal pathology

          -  Post segment pathology including diabetic retinopathy

          -  Dense Posterior subcapsular cataract (PSCC) and Posterior polar cataract (PPC)

          -  High myopic and hyperopic patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haripriya Aravind, MBBS, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aravind Eye Hospital, Madurai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2006</study_first_submitted>
  <study_first_submitted_qc>April 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2006</study_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double-Blind Method</keyword>
  <keyword>Clinical Trials, Randomized</keyword>
  <keyword>Lenses, Intraocular</keyword>
  <keyword>Prospective Studies</keyword>
  <keyword>PMMA</keyword>
  <keyword>Visual acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymethyl Methacrylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

